Microbot Medical Showcases Single-Use LIBERTY Robotic System Ahead of April 2026 Rollout
Microbot Medical’s CEO Harel Gadot will present the FDA-cleared LIBERTY Endovascular Robotic System at the Surgical Disruptive Technology Summit in Houston from February 19 to 21. The single-use, remote-operated system began limited release in late 2025 and targets full market rollout at the April 2026 SIR conference.
1. Conference Participation
Harel Gadot, CEO and Chairman of Microbot Medical, is a featured panelist at the Surgical Disruptive Technology Summit during the SAGES NBT Innovation Weekend in Houston from February 19–21. The session on Endovascular Therapeutics: AI and Robotics will allow the company to highlight LIBERTY’s role in advancing minimally invasive vascular interventions.
2. LIBERTY System Features
The LIBERTY Endovascular Robotic System is the only FDA-cleared, single-use, remotely operated platform for peripheral vascular procedures, designed to enhance precision navigation, reduce radiation exposure and minimize operator strain. Its compact, disposable design aims to remove barriers to wider robotic adoption in endovascular care.
3. Market Release Timeline
Microbot Medical commenced a limited market release of LIBERTY in late 2025 and plans a full commercial launch at the Society of Interventional Radiology conference in April 2026. This staged rollout is intended to deepen clinical adoption and support revenue growth as hospitals integrate robotic endovascular solutions.